Scarica l'app Stockscreener
4.56
1.90%
0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHC Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$4.48
Aprire:
$4.5
Volume 24 ore:
425.28K
Relative Volume:
0.22
Capitalizzazione di mercato:
$1.69B
Reddito:
$9.47B
Utile/perdita netta:
$-178.00M
Rapporto P/E:
-9.50
EPS:
-0.48
Flusso di cassa netto:
$1.01B
1 W Prestazione:
-0.54%
1M Prestazione:
-15.77%
6M Prestazione:
-43.57%
1 anno Prestazione:
-27.88%
Intervallo 1D:
$4.425
$4.595
Intervallo di 1 settimana:
$4.4119
$4.61
Portata 52W:
$3.96
$9.85
Bausch Health Companies Inc Stock (BHC) Company Profile
Nome
Bausch Health Companies Inc
Settore
Telefono
514-744-6792
Indirizzo
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Confronta BHC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
4.565 | 1.70B | 9.47B | -178.00M | 1.01B | -0.48 |
|
HLN
Haleon Plc Adr
|
11.13 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
171.41 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.86 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.97 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.33 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-02 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2024-07-10 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-06-16 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | Downgrade | Truist | Buy → Hold |
| 2022-07-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-06-13 | Ripresa | JP Morgan | Overweight |
| 2021-03-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-02-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-24 | Iniziato | Citigroup | Buy |
| 2020-04-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-02 | Iniziato | Goldman | Neutral |
| 2019-10-25 | Iniziato | Cowen | Outperform |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-08-15 | Aggiornamento | TD Securities | Hold → Buy |
| 2019-07-19 | Iniziato | Wolfe Research | Outperform |
| 2019-06-11 | Ripresa | Barclays | Overweight |
| 2019-05-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-01-02 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | Aggiornamento | Piper Jaffray | Underweight → Neutral |
Mostra tutto
Bausch Health Companies Inc Borsa (BHC) Ultime notizie
The most oversold and overbought stocks on the TSX - The Globe and Mail
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Why Is Bausch (BHC) Down 13% Since Last Earnings Report? - Yahoo Finance
Intraocular Lens Market Is Booming So Rapidly 2025-2032 -Bausch - openPR.com
With 51% institutional ownership, Bausch Health Companies Inc. (NYSE:BHC) is a favorite amongst the big guns - Yahoo Finance
Choroidal Neovascularization Market: Insights Into Retinal - openPR.com
Verteporfin Market Projected to Witness Increased UtilizationNovartis, Valeant Pharmaceuticals - openPR.com
Actinic Keratosis Market Poised Boom | Almirall, S.A, Bausch - openPR.com
Bausch Health’s $7.9 Billion Refinancing Transaction - Global Legal Chronicle
Research Analysts Offer Predictions for TSE:BHC Q2 Earnings - Defense World
Equities Analysts Set Expectations for BHC Q3 Earnings - Defense World
Colonoscopy Bowel Preparation Drugs Market Detailed Analysis - openPR.com
Facial Injectable Market Forecasts Report 2025-2030, - GlobeNewswire
Bausch Health Companies IncEnters Agreements With Icahn, Paulson, Kavanagh GroupsSEC Filing - marketscreener.com
Bausch Health and Bausch + Lomb Brief: Cos Have Cited Amendment to Definitive Proxy Statement Relating to 2025 Annual Meeting of Shareholders On May 21, 2025 - marketscreener.com
Bausch + Lomb’s New Board Agreements Announced - TipRanks
Bausch Health Signs New Board Agreements - TipRanks
Bausch Health Companies Inc. (NYSE:BHC) Receives Average Rating of “Reduce” from Analysts - Defense World
Bausch Health Companies (TSE:BHC) Stock Price Up 1.4% – Time to Buy? - Defense World
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com | FinancialContent - FinancialContent
Balyasny Asset Management L.P. Invests $97,000 in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Global Cataract Surgery Devices Market to grow at a CAGR of 5.50% - openPR.com
Bausch Health Companies Inc. (NYSE:BHC) Stake Lessened by Stifel Financial Corp - Defense World
Bausch, Mylan Settle Patent Suit Over Generic IBS Drugs - Law360
Bausch Health’s CFO Steps In as Interim CAO - TipRanks
India Ophthalmic Devices Market Forecast Report 2025-2033, - GlobeNewswire
Genital Herpes Treatment Market reached US$ 1,143.19 million - openPR.com
Hyperopia Treatment Market Growth, Trends & Opportunities - openPR.com
Bausch Health Elects New Board at Annual Meeting - TipRanks
Bausch Health Announces 2025 Annual Meeting of Shareholder Results - ACCESS Newswire
Bausch Health Annual Meeting: Shareholders Back Board Slate, Executive Pay, and New Stock Plan - Stock Titan
Otoplasty Market Is Booming Worldwide 2025-2032 | Allergan,Bausch Health Companies,Sientra - openPR.com
Bausch + Lomb Brief: Announcing the U.S. Launch of Zenlens CHROMA HOA scleral contact lenses - marketscreener.com
Medical Lasers Market 2025-2032: Emerging Trends, Growth - openPR.com
Oral Mucositis Market Outlook: Trends & Forecast 2024-2031 | - openPR.com
Raymond James Financial Inc. Makes New Investment in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
Mariner LLC Sells 2,340 Shares of Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Bausch health outlines 2025 guidance with 4-5% revenue and EBITDA growth amid strategic refinancing - MSN
Scar Treatment Market Detailed In New Research Report 2025 | - openPR.com
Bausch Health Companies Inc. (BHC): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey
Bausch Health shares fall 39% following InvestingPro’s overvalued warning By Investing.com - Investing.com
Bausch + Lomb Brief: Says Received European CE Mark Approval for Preloaded LuxLife Full Range of Vision Intraocular Lens - marketscreener.com
Bausch Health (BHC) Data Highlights Reduced Rehospitalization wi - GuruFocus
Bausch Health (BHC) Data Highlights Reduced Rehospitalization with Xifaxan Use | BHC Stock News - GuruFocus
Bausch Health Up 3.5% In US Premarket As Says New Analysis Suggests efficacy of Xifaxan - marketscreener.com
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization - voiceofalexandria.com
Bausch Health (BHC) Target Price Reduced by Raymond James | BHC Stock News - GuruFocus
Bausch Health (BHC) Faces Revised Price Target by Raymond James | BHC Stock News - GuruFocus
Bausch Health price target cut to $8 by Raymond James - Investing.com Nigeria
Dry Eye Syndrome Treatment Market Set to Witness Significant - openPR.com
Bausch Health Companies Inc Azioni (BHC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.28%
2.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):